CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AMC-107 | AMC | A Phase 2 Trial of Ixazomib for Kaposi Sarcoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| AMC-115 | AMC | Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AIDS Malignancy Consortium | Adult CIRB - Late Phase Emphasis | Available to Open |
| AMC-108 | AMC | Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma | Adult CIRB - Late Phase Emphasis | Available to Open |
| AMC-111 | AMC | Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study | Adult CIRB - Late Phase Emphasis | Available to Open |
| PEPN2111 | PEP-CTN | A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# TBD) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma | Pediatric CIRB | Available to Open |
| PEPN2011 | PEP-CTN | A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Pediatric CIRB | Available to Open |
| PEPN1812 | PEP-CTN | A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia | Pediatric CIRB | Available to Open |
| PEPN2121 | PEP-CTN | A Phase 2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Pediatric CIRB | Available to Open |
| PEPN1924 | PEP-CTN | A Phase 2 Study of DS-8201A (NSC# 807708, IND# TBD) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma | Pediatric CIRB | Available to Open |
| PED-CITN-03 | Pediatric CITN | Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma | Pediatric CIRB | Available to Open |